These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 31024543)

  • 1. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
    de Leve S; Wirsdörfer F; Jendrossek V
    Front Immunol; 2019; 10():698. PubMed ID: 31024543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.
    de Leve S; Wirsdörfer F; Jendrossek V
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the CD73-adenosine axis in immuno-oncology.
    Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
    Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine and adenosine receptors in colorectal cancer.
    Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
    Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme activity of circulating CD73 in human serum.
    Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
    Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
    Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
    Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
    Harvey JB; Phan LH; Villarreal OE; Bowser JL
    Front Immunol; 2020; 11():508. PubMed ID: 32351498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
    Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
    Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.
    Allard B; Turcotte M; Stagg J
    J Biomed Biotechnol; 2012; 2012():485156. PubMed ID: 23125525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
    Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
    Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
    Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.
    Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J
    PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine pathway and cancer: where do we go from here?
    Antonioli L; Haskó G; Fornai M; Colucci R; Blandizzi C
    Expert Opin Ther Targets; 2014 Sep; 18(9):973-7. PubMed ID: 24958495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.